These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 10147679)

  • 1. CFC replacements: safety testing, approval for use in metered dose inhalers.
    Graepel P; Alexander DJ
    J Aerosol Med; 1991; 4(3):193-200. PubMed ID: 10147679
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Issues surrounding MDI formulation development with non-CFC propellants.
    Kontny MJ; Destefano G; Jager PD; McNamara DP; Turi JS; Van Campen L
    J Aerosol Med; 1991; 4(3):181-7. PubMed ID: 10147677
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The CFC to HFA transition and its impact on pulmonary drug development.
    Leach CL
    Respir Care; 2005 Sep; 50(9):1201-8. PubMed ID: 16122403
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Twenty-eight-day double-blind safety study of an HFA-134a inhalation aerosol system in healthy subjects.
    Harrison LI; Donnell D; Simmons JL; Ekholm BP; Cooper KM; Wyld PJ
    J Pharm Pharmacol; 1996 Jun; 48(6):596-600. PubMed ID: 8832493
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An overview of the toxicology of HFA-134a (1,1,1,2-tetrafluoroethane).
    Alexander DJ; Libretto SE
    Hum Exp Toxicol; 1995 Sep; 14(9):715-20. PubMed ID: 8579881
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human safety and pharmacokinetics of the CFC alternative propellants HFC 134a (1,1,1,2-tetrafluoroethane) and HFC 227 (1,1,1,2,3,3, 3-heptafluoropropane) following whole-body exposure.
    Emmen HH; Hoogendijk EM; Klöpping-Ketelaars WA; Muijser H; Duistermaat E; Ravensberg JC; Alexander DJ; Borkhataria D; Rusch GM; Schmit B
    Regul Toxicol Pharmacol; 2000 Aug; 32(1):22-35. PubMed ID: 11029265
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cumulative dose response study comparing HFA-134a albuterol sulfate and conventional CFC albuterol in patients with asthma.
    Ramsdell JW; Colice GL; Ekholm BP; Klinger NM
    Ann Allergy Asthma Immunol; 1998 Dec; 81(6):593-9. PubMed ID: 9892032
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HFA-134a (1,1,1,2-tetrafluoroethane); lack of oncogenicity in rodents after inhalation.
    Alexander DJ; Libretto SE; Chevalier HJ; Imamura T; Pappritz G; Wilson J
    Hum Exp Toxicol; 1995 Sep; 14(9):706-14. PubMed ID: 8579880
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute, repeated inhalation toxicity, respiratory system irritation, and mutagenicity studies of 1,1,2,2-tetrafluoroethane (HFC-134) as the impurity in the pharmaceutical propellant 1,1,1,2-tetrafluoroethane (HFA-134a).
    Zhao Y; Sun H; Lin F; Yang H
    Drug Chem Toxicol; 2023 Nov; 46(5):841-850. PubMed ID: 35920286
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Albuterol HFA is as effective as albuterol CFC in preventing exercise-induced bronchoconstriction.
    Hawksworth RJ; Sykes AP; Faris M; Mant T; Lee TH
    Ann Allergy Asthma Immunol; 2002 May; 88(5):473-7. PubMed ID: 12027068
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety of propellants.
    Alexander DJ
    J Aerosol Med; 1995; 8 Suppl 1():S29-34. PubMed ID: 10150492
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tolerability and in vivo performance of a novel freon-free metered dose inhaler for a fixed combinational product of reproterol and disodium cromoglycate.
    Hermann R; Ruus P; Schneider E; de Mey C
    Arzneimittelforschung; 1998 Jun; 48(6):663-7. PubMed ID: 9689424
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The technical transition to CFC-free inhalers.
    Tansey I
    Br J Clin Pract Suppl; 1997 May; 89():22-7. PubMed ID: 9519509
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized, double-blind, double-dummy, single-dose, efficacy crossover trial comparing formoterol-HFA (pMDI) versus formoterol-DPI (Aerolizer) and placebo (pMDI or Aerolizer) in asthmatic patients.
    Bousquet J; Huchon G; Leclerc V; Vicaut E; Lefrançois G
    Respiration; 2005; 72 Suppl 1():6-12. PubMed ID: 15915007
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reformulation of Stmerin(®) D CFC formulation using HFA propellants.
    Murata S; Izumi T; Ito H
    Pharm Dev Technol; 2013; 18(6):1314-8. PubMed ID: 22519407
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Compatibility evaluation of metered-dose inhaler valve elastomers with tetrafluoroethane (P134a), a non-CFC propellant.
    Tiwari D; Goldman D; Dixit S; Malick WA; Madan PL
    Drug Dev Ind Pharm; 1998 Apr; 24(4):345-52. PubMed ID: 9876594
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The change to non-CFC metered dose inhalers.
    Rubinfeld A
    Aust Fam Physician; 1997 Dec; 26(12):1412-4. PubMed ID: 9470296
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transition to CFC-free metered dose inhalers--into the new millennium.
    McDonald KJ; Martin GP
    Int J Pharm; 2000 May; 201(1):89-107. PubMed ID: 10867268
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of mometasone furoate dry powder inhaler and beclomethasone dipropionate hydrofluoroalkane and chlorofluorocarbon on the hypothalamic-pituitary-adrenal axis in asthmatic subjects.
    Chrousos GP; Ghaly L; Shedden A; Iezzoni DG; Harris AG
    Chest; 2005 Jul; 128(1):70-7. PubMed ID: 16002918
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The challenge of reformulation.
    Smith IJ
    J Aerosol Med; 1995; 8 Suppl 1():S19-27. PubMed ID: 10150491
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.